-
1
-
-
0032547326
-
Randomised trial of oestrogen plus progesterone is secondary prevention of coronary heart disease in postmenopausal women
-
The heart and estrogen/progestin replacement study research group (HERS)
-
The heart and estrogen/progestin replacement study research group (HERS). Randomised trial of oestrogen plus progesterone is secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13.
-
(1998)
JAMA
, vol.280
, pp. 605-613
-
-
-
2
-
-
0037014584
-
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II)
-
Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 2002;288:49-57.
-
(2002)
JAMA
, vol.288
, pp. 49-57
-
-
Grady, D.1
Herrington, D.2
Bittner, V.3
Blumenthal, R.4
Davidson, M.5
Hlatky, M.6
-
3
-
-
0037125379
-
Risks and benefits of estrogen plus progestin in healthy menopausal women. Principal results from the WHI randomised controlled trial
-
Writing group for the Women's Health Initiative (WHI) investigators
-
Writing group for the Women's Health Initiative (WHI) investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women. Principal results from the WHI randomised controlled trial. JAMA 2002;288:321-33.
-
(2002)
JAMA
, vol.288
, pp. 321-333
-
-
-
4
-
-
0042018741
-
Breast cancer and hormone replacement therapy in the Million Women Study
-
for the Million Women study collaborators
-
Beral V for the Million Women study collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
-
(2003)
Lancet
, vol.362
, pp. 419-427
-
-
Beral, V.1
-
5
-
-
0003954079
-
Osteoporosis: Clinical guidelines for prevention and treatment
-
Royal College of Physicians Available at: www. rcplondon.ac.uk (accessed on 4 November)
-
Royal College of Physicians. Osteoporosis: clinical guidelines for prevention and treatment. Available at: www. rcplondon.ac.uk (accessed on 4 November 2003).
-
(2003)
-
-
-
6
-
-
0030843969
-
Breast cancer and hormone replacement therapy. Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
-
Collaborative group on hormonal factors in breast cancer
-
Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy. Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59.
-
(1997)
Lancet
, vol.350
, pp. 1047-1059
-
-
-
7
-
-
0031058448
-
Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women
-
Beresford SA, Weiss N, Voigt L, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women. Lancet 1997;349:458-61.
-
(1997)
Lancet
, vol.349
, pp. 458-461
-
-
Beresford, S.A.1
Weiss, N.2
Voigt, L.3
McKnight, B.4
-
8
-
-
0037151453
-
Postmenopausal hormone replacement therapy: Scientific review
-
Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-81.
-
(2002)
JAMA
, vol.288
, pp. 872-881
-
-
Nelson, H.D.1
Humphrey, L.L.2
Nygren, P.3
Teutsch, S.M.4
Allan, J.D.5
|